The diabetes treatment devices market size has grown strongly in recent years. It will grow from $12.34 billion in 2025 to $13.11 billion in 2026 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to reliance on traditional blood glucose meters, limited awareness of self-monitoring devices, growing hospital and diagnostic center infrastructure, increasing prevalence of diabetes, adoption of standard lancets and testing strips.
The diabetes treatment devices market size is expected to see strong growth in the next few years. It will grow to $16.53 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of smart insulin pens and pumps, rising adoption of real-time continuous glucose monitoring, integration with smartphones and wearable devices, increasing remote patient monitoring programs, expansion of diabetes clinics and online distribution channels. Major trends in the forecast period include rising adoption of continuous glucose monitoring devices, increasing preference for smart insulin delivery systems, growth in homecare and remote patient monitoring, expansion of wearable and handheld glucometers, rising demand for safety-enhanced lancets and testing strips.
The rising obesity rates are anticipated to drive the expansion of the diabetes treatment devices market in the coming years. Obesity rate indicates the proportion of individuals identified as obese based on their body mass index (BMI). The surge in obesity is largely attributed to unhealthy diets rich in calories, sugars, and fats, which result in excessive weight gain when not offset by physical activity. Diabetes treatment devices contribute to lowering obesity rates by supporting improved blood sugar management, which encourages healthier lifestyle practices and effective weight control. For example, in September 2024, the US Centers for Disease Control and Prevention (CDC), a national public-health agency in the US, reported that adult obesity rates reached 35% or higher in 23 US states in 2023, up from 22 states in 2022, reflecting a worsening obesity trend. As a result, the increasing obesity rates are fueling growth in the diabetes treatment devices market.
Major companies in the diabetes treatment devices market are increasingly focusing on integrating advanced automation technologies, such as automated insulin delivery algorithms, to improve treatment accuracy and continuous glycemic management. These algorithms leverage real-time glucose data from continuous glucose monitoring sensors to automatically modify basal insulin dosing, aiding in maintaining glucose levels within the desired range with minimal manual effort. For example, in April 2023, Medtronic plc, a US-based medical technology firm, obtained FDA approval for the MiniMed 780G System, an automated insulin delivery solution designed for people with type 1 diabetes. This system automatically corrects high glucose levels and adjusts insulin delivery every five minutes. It includes SmartGuard technology for real-time glucose-responsive insulin adjustments, Bluetooth connectivity for mobile monitoring, and integrated support for continuous glucose monitoring. The MiniMed 780G System enhances treatment precision, glucose stability, and overall day-to-day diabetes management outcomes.
In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed sum. This acquisition enables Abbott Laboratories to combine continuous glucose monitoring with smart insulin dosing technology, aiming to deliver more personalized, connected, and accessible diabetes care. Bigfoot Biomedical Inc. is a US-based medical technology company that specializes in developing and providing diabetes treatment devices.
Major companies operating in the diabetes treatment devices market are Johnson And Johnson, Abbott Laboratories, Medtronic plc, Becton Dickinson And Company, Hoffmann-La Roche Ltd, Insulet Corporation, DexCom Inc, Tandem Diabetes Care Inc, Lifescan Inc, Ypsomed Holding AG, Ascensia Diabetes Care Holdings AG, B Braun Melsungen AG, Beta Bionics Inc, Senseonics Holdings Inc, Bigfoot Biomedical Inc, Medtrum Technologies Inc, Diabeloop SA, Roche Diabetes Care GmbH, Insulet Inc, Omnipod Inc, Tandem Inc, Abbott Diabetes Care.
North America was the largest region in the diabetes treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the diabetes treatment devices market by increasing the cost of imported sensors, transmitters, and smart insulin delivery devices. Segments such as continuous glucose monitoring devices and smart insulin pumps are most impacted, particularly in regions like Asia-Pacific and North America that rely heavily on imports. This has led to higher device prices and potential supply chain delays. However, tariffs have also encouraged local manufacturing, investment in domestic production facilities, and development of cost-optimized devices for regional markets.
The diabetes treatment devices market research report is one of a series of new reports that provides diabetes treatment devices market statistics, including diabetes treatment devices industry global market size, regional shares, competitors with a diabetes treatment devices market share, detailed diabetes treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes treatment devices industry. This diabetes treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Diabetes treatment devices are specialized medical tools designed to help individuals manage and treat diabetes by monitoring blood sugar levels, administering insulin, or addressing related health concerns. These devices play a crucial role in helping patients achieve optimal blood glucose control and prevent complications linked to diabetes.
The primary types of diabetes treatment devices include blood glucose monitoring devices, self-monitoring tools, blood glucose meters, testing strips, lancets, continuous glucose monitoring devices, sensors, transmitters, receivers, and other related equipment. Blood glucose monitoring devices are essential for measuring blood sugar levels, assisting individuals in effectively managing their diabetes. These devices are available through various distribution channels, including hospital pharmacies, retail pharmacies, diabetes clinics, institutional sales, and online pharmacies. They cater to a wide range of users, such as hospitals, homecare settings, diagnostic centers, ambulatory surgery centers, and other healthcare facilities.
The diabetes treatment devices market consists of sales of smart insulin pens, artificial pancreas systems, closed-loop systems, and jet injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The diabetes treatment devices market size is expected to see strong growth in the next few years. It will grow to $16.53 billion in 2030 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to development of smart insulin pens and pumps, rising adoption of real-time continuous glucose monitoring, integration with smartphones and wearable devices, increasing remote patient monitoring programs, expansion of diabetes clinics and online distribution channels. Major trends in the forecast period include rising adoption of continuous glucose monitoring devices, increasing preference for smart insulin delivery systems, growth in homecare and remote patient monitoring, expansion of wearable and handheld glucometers, rising demand for safety-enhanced lancets and testing strips.
The rising obesity rates are anticipated to drive the expansion of the diabetes treatment devices market in the coming years. Obesity rate indicates the proportion of individuals identified as obese based on their body mass index (BMI). The surge in obesity is largely attributed to unhealthy diets rich in calories, sugars, and fats, which result in excessive weight gain when not offset by physical activity. Diabetes treatment devices contribute to lowering obesity rates by supporting improved blood sugar management, which encourages healthier lifestyle practices and effective weight control. For example, in September 2024, the US Centers for Disease Control and Prevention (CDC), a national public-health agency in the US, reported that adult obesity rates reached 35% or higher in 23 US states in 2023, up from 22 states in 2022, reflecting a worsening obesity trend. As a result, the increasing obesity rates are fueling growth in the diabetes treatment devices market.
Major companies in the diabetes treatment devices market are increasingly focusing on integrating advanced automation technologies, such as automated insulin delivery algorithms, to improve treatment accuracy and continuous glycemic management. These algorithms leverage real-time glucose data from continuous glucose monitoring sensors to automatically modify basal insulin dosing, aiding in maintaining glucose levels within the desired range with minimal manual effort. For example, in April 2023, Medtronic plc, a US-based medical technology firm, obtained FDA approval for the MiniMed 780G System, an automated insulin delivery solution designed for people with type 1 diabetes. This system automatically corrects high glucose levels and adjusts insulin delivery every five minutes. It includes SmartGuard technology for real-time glucose-responsive insulin adjustments, Bluetooth connectivity for mobile monitoring, and integrated support for continuous glucose monitoring. The MiniMed 780G System enhances treatment precision, glucose stability, and overall day-to-day diabetes management outcomes.
In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed sum. This acquisition enables Abbott Laboratories to combine continuous glucose monitoring with smart insulin dosing technology, aiming to deliver more personalized, connected, and accessible diabetes care. Bigfoot Biomedical Inc. is a US-based medical technology company that specializes in developing and providing diabetes treatment devices.
Major companies operating in the diabetes treatment devices market are Johnson And Johnson, Abbott Laboratories, Medtronic plc, Becton Dickinson And Company, Hoffmann-La Roche Ltd, Insulet Corporation, DexCom Inc, Tandem Diabetes Care Inc, Lifescan Inc, Ypsomed Holding AG, Ascensia Diabetes Care Holdings AG, B Braun Melsungen AG, Beta Bionics Inc, Senseonics Holdings Inc, Bigfoot Biomedical Inc, Medtrum Technologies Inc, Diabeloop SA, Roche Diabetes Care GmbH, Insulet Inc, Omnipod Inc, Tandem Inc, Abbott Diabetes Care.
North America was the largest region in the diabetes treatment devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetes treatment devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetes treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the diabetes treatment devices market by increasing the cost of imported sensors, transmitters, and smart insulin delivery devices. Segments such as continuous glucose monitoring devices and smart insulin pumps are most impacted, particularly in regions like Asia-Pacific and North America that rely heavily on imports. This has led to higher device prices and potential supply chain delays. However, tariffs have also encouraged local manufacturing, investment in domestic production facilities, and development of cost-optimized devices for regional markets.
The diabetes treatment devices market research report is one of a series of new reports that provides diabetes treatment devices market statistics, including diabetes treatment devices industry global market size, regional shares, competitors with a diabetes treatment devices market share, detailed diabetes treatment devices market segments, market trends and opportunities, and any further data you may need to thrive in the diabetes treatment devices industry. This diabetes treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Diabetes treatment devices are specialized medical tools designed to help individuals manage and treat diabetes by monitoring blood sugar levels, administering insulin, or addressing related health concerns. These devices play a crucial role in helping patients achieve optimal blood glucose control and prevent complications linked to diabetes.
The primary types of diabetes treatment devices include blood glucose monitoring devices, self-monitoring tools, blood glucose meters, testing strips, lancets, continuous glucose monitoring devices, sensors, transmitters, receivers, and other related equipment. Blood glucose monitoring devices are essential for measuring blood sugar levels, assisting individuals in effectively managing their diabetes. These devices are available through various distribution channels, including hospital pharmacies, retail pharmacies, diabetes clinics, institutional sales, and online pharmacies. They cater to a wide range of users, such as hospitals, homecare settings, diagnostic centers, ambulatory surgery centers, and other healthcare facilities.
The diabetes treatment devices market consists of sales of smart insulin pens, artificial pancreas systems, closed-loop systems, and jet injectors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Diabetes Treatment Devices Market Characteristics
3. Diabetes Treatment Devices Market Supply Chain Analysis
4. Global Diabetes Treatment Devices Market Trends and Strategies
5. Diabetes Treatment Devices Market Analysis of End Use Industries
7. Global Diabetes Treatment Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Diabetes Treatment Devices Total Addressable Market (TAM) Analysis for the Market
9. Diabetes Treatment Devices Market Segmentation
10. Diabetes Treatment Devices Market Regional and Country Analysis
11. Asia-Pacific Diabetes Treatment Devices Market
12. China Diabetes Treatment Devices Market
13. India Diabetes Treatment Devices Market
14. Japan Diabetes Treatment Devices Market
15. Australia Diabetes Treatment Devices Market
16. Indonesia Diabetes Treatment Devices Market
17. South Korea Diabetes Treatment Devices Market
18. Taiwan Diabetes Treatment Devices Market
19. South East Asia Diabetes Treatment Devices Market
20. Western Europe Diabetes Treatment Devices Market
21. UK Diabetes Treatment Devices Market
22. Germany Diabetes Treatment Devices Market
23. France Diabetes Treatment Devices Market
24. Italy Diabetes Treatment Devices Market
25. Spain Diabetes Treatment Devices Market
26. Eastern Europe Diabetes Treatment Devices Market
27. Russia Diabetes Treatment Devices Market
28. North America Diabetes Treatment Devices Market
29. USA Diabetes Treatment Devices Market
30. Canada Diabetes Treatment Devices Market
31. South America Diabetes Treatment Devices Market
32. Brazil Diabetes Treatment Devices Market
33. Middle East Diabetes Treatment Devices Market
34. Africa Diabetes Treatment Devices Market
36. Diabetes Treatment Devices Market Competitive Landscape and Company Profiles
37. Diabetes Treatment Devices Market Other Major and Innovative Companies
40. Diabetes Treatment Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Diabetes Treatment Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses diabetes treatment devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for diabetes treatment devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The diabetes treatment devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Device Type: Blood Glucose Monitoring Devices; Self-Monitoring Devices; Blood Glucose Meters; Testing Strips; Lancets; Continuous Glucose Monitoring Devices; Sensors; Transmitters; Receiver; Other Device Types2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Diabetes Clinics Or Centers; Institutional Sales; Online Pharmacies; Other Distribution Channels
3) By End-User: Hospitals; Homecare; Diagnostic Centers; Ambulatory Surgery Centers; Other End-Users
Subsegments:
1) By Blood Glucose Monitoring Devices: Invasive Blood Glucose Monitoring Devices; Non-Invasive Blood Glucose Monitoring Devices2) By Self-Monitoring Devices: Handheld Glucometers; Wearable Self-Monitoring Devices
3) By Blood Glucose Meters: Standard Glucose Meters; Smart Or Connected Glucose Meters
4) By Testing Strips: Glucose Oxidase Strips; Glucose Dehydrogenase Strips
5) By Lancets: Standard Lancets; Safety Lancets
6) By Continuous Glucose Monitoring Devices: Real-Time Continuous Glucose Monitoring Devices; Intermittently Scanned Continuous Glucose Monitoring Devices
7) By Sensors: Short-Term Sensors; Long-Term Implantable Sensors
8) By Transmitters: Reusable Transmitters; Disposable Transmitters
9) By Receiver: Dedicated Continuous Glucose Monitoring Devices Monitors; Smartphone Or Smartwatch-Connected Receivers
10) By Other Device Types: Insulin Pens; Insulin Pumps; Smart Insulin Patches
Companies Mentioned: Johnson And Johnson; Abbott Laboratories; Medtronic plc; Becton Dickinson And Company; Hoffmann-La Roche Ltd; Insulet Corporation; DexCom Inc; Tandem Diabetes Care Inc; Lifescan Inc; Ypsomed Holding AG; Ascensia Diabetes Care Holdings AG; B Braun Melsungen AG; Beta Bionics Inc; Senseonics Holdings Inc; Bigfoot Biomedical Inc; Medtrum Technologies Inc; Diabeloop SA; Roche Diabetes Care GmbH; Insulet Inc; Omnipod Inc; Tandem Inc; Abbott Diabetes Care
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Diabetes Treatment Devices market report include:- Johnson And Johnson
- Abbott Laboratories
- Medtronic plc
- Becton Dickinson And Company
- Hoffmann-La Roche Ltd
- Insulet Corporation
- DexCom Inc
- Tandem Diabetes Care Inc
- Lifescan Inc
- Ypsomed Holding AG
- Ascensia Diabetes Care Holdings AG
- B Braun Melsungen AG
- Beta Bionics Inc
- Senseonics Holdings Inc
- Bigfoot Biomedical Inc
- Medtrum Technologies Inc
- Diabeloop SA
- Roche Diabetes Care GmbH
- Insulet Inc
- Omnipod Inc
- Tandem Inc
- Abbott Diabetes Care
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 13.11 Billion |
| Forecasted Market Value ( USD | $ 16.53 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
